Delving into the Latest Updates on Neovia Oncology, Inc. with Synapse

概览

关联

1

项与 Neovia Oncology, Inc. 相关的药物

Camptothecin/Podophyllotoxin

喜树碱/鬼臼毒素

靶点

TOP1 x Tubulin

作用机制

TOP1抑制剂 [+1]

在研机构-

原研机构

Neovia Oncology, Inc.

在研适应症-

非在研适应症

晚期癌症 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 Neovia Oncology, Inc. 相关的临床试验

NCT02797795 / Unknown status临床1期

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies

This study is a first-in-human, multicenter, open-label, nonrandomized, dose-escalation trial to be conducted in 2 sequential parts:
Part A (Dose Escalation) in subjects with advanced malignancies
Part B (Dose Confirmation) in subjects with tumor type(s) to be determined by results of Part A

开始日期2016-12-01

申办/合作机构

Neovia Oncology, Inc.

100 项与 Neovia Oncology, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Neovia Oncology, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Neovia Oncology, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Neovia Oncology, Inc. 相关的转化医学

登录后查看更多信息